---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-038902"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:51:03.478990+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Surrozen reports Phase 1a SZN-043 data: safe, target engagement, liver function effects; Phase 1b starts

## Summary
- Phase 1a enrolled 48 subjects (40 healthy, 8 cirrhotic); doses 0.5-3 mg/kg IV; no serious adverse events.
- Demonstrated target engagement via transient ALP increases and Wnt pathway activation by methacetin breath test.
- In cirrhotic patients, dose-dependent pharmacodynamic effect and improvement in liver function via HepQuant test observed.
- Initiating Phase 1b proof-of-concept trial in severe alcohol-associated hepatitis; data expected first half 2025.

## SEC filing metadata
- accession: 0000950170-24-038902
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017024038902/0000950170-24-038902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017024038902/srzn-20240401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-038902
- JSON: https://secwatch.observer/filing/0000950170-24-038902.json
- Plain text: https://secwatch.observer/filing/0000950170-24-038902.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.